Compare Danaher Corporation (DHR) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares Core S&P 500 ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 5.9× Danaher Corporation's market cap, and Danaher Corporation pays a 0.74% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares Core S&P 500 ETF for 46 Days on average.
| DHR | IVV | |
|---|---|---|
Market Cap | $152.87B | $897.20B |
Volume | 5,228,698 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $782.58 |
52-Week Low | $161.91 | $634.93 |
Typical Hold Time | 69 Days | 46 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
IVV, tracking the S&P 500, trades at $781.97 with a slight 0.18% daily gain. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights mixed sentiment with concerns about profit growth slowing from 35% in 2026 to 15% in 2027 (24/7 Wall Street, 2026-10-03), though some analysts project a year-end rally (Citadel strategist, 2026-10-02). The ETF remains a core holding for broad market exposure amid ongoing economic uncertainties.
The outlook for IVV is cautiously optimistic, supported by bullish technicals and historical seasonal patterns. Key opportunities include potential upside from AI-driven earnings growth and index composition changes like Twilio's addition (Market Watch, 2026-10-01). Risks center on concentration in top holdings, rising interest rates, and geopolitical tensions that could dampen broader market performance. Investors should weigh the ETF's low-cost diversification against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
